Ops, QA staff escape Genzyme's ($GENZ) job cuts

Genzyme ($GENZ) last week cut 392 filled and unfilled jobs at several locations, executing the first step in its plan to eliminate 1,000 by the end of next year. Employees got the word on Thursday.

The 1,000 represents about one-twelfth of the Cambridge, MA, biotech's workforce.

Some 185 of those cuts are in Massachusetts, but not at the troubled Allston manufacturing plant. The plant is currently operating under a consent decree with the FDA for remediation of manufacturing shortcomings. The company has been and continues to hire manufacturing and quality assurance employees, says the Boston Globe. Plans call for an additional 500 to 600 such jobs in Allston, Framingham, and elsewhere by the end of next year.

- see the article
- here's the Globe report

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.